Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors

Journal of Molecular Endocrinology

Volumn 44, Issue 3, 2010, Pages 143-154

  Lu, Changxue ^a   Cheng, Sheue Yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BEZAFIBRATE; CELL NUCLEUS RECEPTOR; CIGLITAZONE; CIPROFIBRATE; CLOFIBRATE; FARGLITAZAR; FENOFIBRATE; GEMFIBROZIL; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; RIVOGLITAZONE; ROSIGLITAZONE; THYROID HORMONE RECEPTOR; TROGLITAZONE;

ADIPOGENESIS; CARCINOGENESIS; CELL FUNCTION; COLON POLYP; DIABETES MELLITUS; GENE EXPRESSION; HORMONE RESPONSE; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADIPOGENESIS; ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION;

EID: 76649093590     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-09-0107     Document Type: Review

References (101)

1. Araki O, Ying H, Furuya F, Zhu X & Cheng SY 2005 Thyroid hormone receptor beta mutants: dominant negative regulators of peroxisome proliferator-activated receptor γ action. PNAS 102 16251-16256.
2. Araki O, Ying H, Zhu XG, Willingham MC & Cheng SY 2009 Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Molecular Endocrinology 23 308-315.
3. Balakumar P, Rose M & Singh M 2007 PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 80 1-10.
4. Barish GD, Narkar VA & Evans RM 2006 PPAR delta: a dagger in the heart of the metabolic syndrome. Journal of Clinical Investigation 116 590-597.
5. Baxter JD & Webb P 2009 Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nature Reviews. Drug Discovery 8 308-320.
6. Baxter JD, Webb P, Grover G & Scanlan TS 2004 Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends in Endocrinology and Metabolism 15 154-157.
7. Bensinger SJ & Tontonoz P 2008 Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454 470-477.
8. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y et al. 1999 Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARdelta ligands produce distinct biological effects. Journal of Biological Chemistry 274 6718-6725.
9. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S & Davis PJ 2005 Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146 2864-2871.
10. Bogazzi F, Hudson LD & Nikodem VM 1994 A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferator-activated receptor. Journal of Biological Chemistry 269 11683-11686.
11. Bonilla S, Redonnet A, Noel-Suberville C, Groubet R, Pallet V & Higueret P 2001 Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver. Journal of Physiology and Biochemistry 57 1-8.
12. Brent GA, Larsen PR, Harney JW, Koenig RJ & Moore DD 1989 Functional characterization of the rat growth hormone promoter elements required for induction by thyroid hormone with and without a co-transfected beta type thyroid hormone receptor. Journal of Biological Chemistry 264 178-182.
13. Casas F, Rochard P, Rodier A, Cassar-Malek I, Marchal-Victorion S, Wiesner RJ, Cabello G & Wrutniak C 1999 A variant form of the nuclear triiodothyronine receptor c-ErbAalpha1 plays a direct role in regulation of mitochondrial RNA synthesis. Molecular and Cellular Biology 19 7913-7924.
14. 3 receptor p43 induces a shift in skeletal muscle fiber types. PLoS ONE 3 e2501.
15. Chassande O, FraichardA,Gauthier K, Flamant F, Legrand C, Savatier P, Laudet V & Samarut J 1997 Identification of transcripts initiated from an internal promoter in the c-erbA alpha locus that encode inhibitors of retinoic acid receptor-alpha and triiodothyronine receptor activities. Molecular Endocrinology 11 1278-1290.
16. Chen Y, Wang SM, Wu JC & Huang SH 2006 Effects of PPARγ agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line. Journal of Cellular Biochemistry 98 1021-1035.
17. Chen RN, Huang YH, Lin YC, Yeh CT, Liang Y, Chen SL & Lin KH 2008 Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines. Endocrinology 149 3817-3831.
18. 3 signaling pathways. PNAS 92 11593-11597.
19. Davies SS, Pontsler AV, Marathe GK, Harrison KA, Murphy RC, Hinshaw JC, Prestwich GD, Hilaire AS, Prescott SM, Zimmerman GA et al. 2001 Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator- activated receptor γ ligands and agonists. Journal of Biological Chemistry 276 16015-16023.
20. Espadinha C, Cavaco BM & Leite V 2007 PAX8PPARγ stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line. Thyroid 17 497-509.
21. Esquenet M, Swinnen JV, Heyns W & Verhoeven G 1995 Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Molecular and Cellular Endocrinology 109 105-111.
22. Fajas L, Debril MB & Auwerx J 2001 Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. Journal of Molecular Endocrinology 27 1-9.
23. Farsetti A, Desvergne B, Hallenbeck P, Robbins J & Nikodem VM 1992 Characterization of myelin basic protein thyroid hormone response element and its function in the context of native and heterologous promoter. Journal of Biological Chemistry 267 15784-15788.
24. Festuccia WT, Oztezcan S, Laplante M, Berthiaume M, Michel C, Dohgu S, Denis RG, Brito MN, Brito NA, Miller DS et al. 2008 Peroxisome proliferator-activated receptor-γ-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 149 2121-2130.
25. Flores-Morales A, Gullberg H, Fernandez L, Stahlberg N, Lee NH, Vennstrom B & Norstedt G 2002 Patterns of liver gene expression governed by TRbeta. Molecular Endocrinology 16 1257-1268.
26. Forman BM, Casanova J, Raaka BM, Ghysdael J & Samuels HH 1992 Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. Molecular Endocrinology 6 429-442.
27. 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell 83 803-812.
28. Furnsinn C, Willson TM & Brunmair B 2007 Peroxisome proliferatoractivated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 50 8-17.
29. Furuya F, Guigon CJ, Zhao L, Lu C, Hanover JA & Cheng SY 2007 Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling. Molecular and Cellular Biology 27 6116-6126.
30. Fyffe SA, Alphey MS, Buetow L, Smith TK, Ferguson MA, Sorensen MD, Bjorkling F & Hunter WN 2006 Recombinant human PPARbeta/ delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. Journal of Molecular Biology 356 1005-1013.
31. Gardner OS, Dewar BJ & Graves LM 2005 Activation of mitogenactivated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Molecular Pharmacology 68 933-941.
32. Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z et al. 2006 Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clinical Cancer Research 12 1983-1993.
33. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar P, Rosenberg DW, Bronson RT, Edelmann W et al. 2002 APC-dependent suppression of colon carcinogenesis by PPARγ. PNAS 99 13771-13776.
34. Glass CK, Holloway JM, Devary OV & Rosenfeld MG 1988 The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements. Cell 54 313-323.
35. Gregory Powell J, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK et al. 2004 The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 23 3634-3641.
36. Grover GJ, Mellstrom K, Ye L, Malm J, Li YL, Bladh LG, Sleph PG, Smith MA, George R, Vennstrom B et al. 2003 Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. PNAS 100 10067-10072.
37. Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC & Kim BW 2009 Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-γ agonists in skeletal myocytes. Endocrinology 150 1976-1983.
38. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ & Peters JM 2004 Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nature Medicine 10 481-483.
39. Harris SG & Phipps RP 2001 The nuclear receptor PPAR γ is expressed by mouse T lymphocytes and PPAR γ agonists induce apoptosis. European Journal of Immunology 31 1098-1105.
40. Harvey CB, Bassett JH, Maruvada P, Yen PM & Williams GR 2007 The rat thyroid hormone receptor (TR) Deltabeta3 displays cell-, TR isoform-, and thyroid hormone response element-specific actions. Endocrinology 148 1764-1773.
41. Hashimoto K, Ethridge RT & Evers BM 2002 Peroxisome proliferatoractivated receptor g ligand inhibits cell growth and invasion of human pancreatic cancer cells. International Journal of Gastrointestinal Cancer 32 7-22.
42. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK et al. 2009 Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49 1563-1570.
43. Hodin RA, Lazar MA, Wintman BI, Darling DS, Koenig RJ, Larsen PR, Moore DD & Chin WW 1989 Identification of a thyroid hormone receptor that is pituitary-specific. Science 244 76-79.
44. Holness MJ, Greenwood GK, Smith ND & SugdenMC 2008 PPARalpha activation and increased dietary lipid oppose thyroid hormone signaling and rescue impaired glucose-stimulated insulin secretion in hyperthyroidism. American Journal of Physiology. Endocrinology and Metabolism 295 E1380-E1389.
45. Horkko TT, Tuppurainen K, George SM, Jernvall P, Karttunen TJ & Makinen MJ 2006 Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. International Journal of Cancer 118 1653-1659.
46. Hulit J,Wang C, Li Z, Albanese C, RaoM, Di Vizio D, Shah S, Byers SW, Mahmood R, Augenlicht LH et al. 2004 Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Molecular and Cellular Biology 24 7598-7611.
47. Hunter J, Kassam A, Winrow CJ, Rachubinski RA & Capone JP 1996 Crosstalk between the thyroid hormone and peroxisome proliferator-activated receptors in regulating peroxisome proliferator-responsive genes. Molecular and Cellular Endocrinology 116 213-221.
48. Iishi H, Tatsuta M, Baba M, Yamamoto R & Taniguchi H 1993 Enhancement by thyroxine of gastric carcinogenesis induced by N-methyl-N′- nitro-N-nitrosoguanidine in Wistar rats. British Journal of Cancer 68 515-518.
49. Izumo S & Mahdavi V 1988 Thyroid hormone receptor alpha isoforms generated by alternative splicing differentially activate myosin HC gene transcription. Nature 334 539-542.
50. Jatwa R, Parmar HS, Panda S & Kar A 2007 Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice. Basic Clinical Pharmacology & Toxicology 101 177-180.
51. Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, Lemberger T, Wahli W, Burger AG & Meier CA 1995 Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat. Journal of Biological Chemistry 270 18117-18122.
52. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA, Kazlauskaite R, Pankratz DG, Wynshaw-Boris A, Refetoff S et al. 2000 Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. PNAS 97 13209-13214.
53. Kaneshige M, Suzuki H, Kaneshige K, Cheng J, Wimbrow H, Barlow C, Willingham MC & Cheng S 2001 A targeted dominant negative mutation of the thyroid hormone alpha 1 receptor causes increased mortality, infertility, and dwarfism in mice. PNAS 98 15095-15100.
54. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC & Cheng SY 2006 PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 25 2736-2747.
55. Kliewer SA, Umesono K, Noonan DJ, Heyman RA & Evans RM 1992 Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358 771-774.
56. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC & Lehmann JM 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83 813-819.
57. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM et al. 1997 Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. PNAS 94 4318-4323.
58. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM & Fletcher JA 2000 PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289 1357-1360.
59. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M & Bidart JM 2005 Follicular thyroid tumors with the PAX8-PPARγ1 rearrangement display characteristic genetic alterations. American Journal of Pathology 167 223-231.
60. de Lange P, Feola A, Ragni M, Senese R, Moreno M, Lombardi A, Silvestri E, Amat R, Villarroya F, Goglia F et al. 2007 Differential 3,5,3′-triiodothyronine-mediated regulation of uncoupling protein 3 transcription: role of fatty acids. Endocrinology 148 4064-4072.
61. Lazar MA 1993 Thyroid hormone receptors: multiple forms, multiple possibilities. Endocrine Reviews 14 184-193.
62. Ledda-Columbano GM, Perra A, Piga R, Pibiri M, Loi R, Shinozuka H & Columbano A 1999 Cell proliferation induced by 3,3′,5-triiodo-Lthyronine is associated with a reduction in the number of preneoplastic hepatic lesions. Carcinogenesis 20 2299-2304.
63. Liu YY, Heymann RS, Moatamed F, Schultz JJ, Sobel D & Brent GA 2007 A mutant thyroid hormone receptor alpha antagonizes peroxisome proliferator-activated receptor alpha signaling in vivo and impairs fatty acid oxidation. Endocrinology 148 1206-1217.
64. Lui WO, Foukakis T, Liden J, Thoppe SR, Dwight T, Hoog A, Zedenius J, Wallin G, Reimers M & Larsson C 2005 Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene. Oncogene 24 1467-1476.
65. Lui WO, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan EL, Leibiger I, Leibiger B, Enberg U, Hoog A et al. 2008 CREB3L2-PPARγ fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Research 68 7156-7164.
66. Macchia PE, Takeuchi Y, Kawai T, Cua K, Gauthier K, Chassande O, Seo H, Hayashi Y, Samarut J, Murata Y et al. 2001 Increased sensitivity to thyroid hormone in mice with complete deficiency of thyroid hormone receptor alpha. PNAS 98 349-354.
67. Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennstrom B & Aranda A 2009 Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Research 69 501-509.
68. Meier-Heusler SC, Zhu X, Juge-Aubry C, Pernin A, Burger AG, Cheng SY & Meier CA 1995 Modulation of thyroid hormone action by mutant thyroid hormone receptors, c-erbA alpha 2 and peroxisome proliferator-activated receptor: evidence for different mechanisms of inhibition. Molecular and Cellular Endocrinology 107 55-66.
69. Mitsuhashi T, Tennyson GE & Nikodem VM 1988 Alternative splicing generates messages encoding rat c-erbA proteins that do not bind thyroid hormone. PNAS 85 5804-5808.
70. Miyamoto T, Kaneko A, Kakizawa T, Yajima H, Kamijo K, Sekine R, Hiramatsu K, Nishii Y, Hashimoto T &Hashizume K 1997 Inhibition of peroxisome proliferator signaling pathways by thyroid hormone receptor. Competitive binding to the response element. Journal of Biological Chemistry 272 7752-7758.
71. Motomura W, Okumura T, Takahashi N, Obara T & Kohgo Y 2000 Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Research 60 5558-5564.
72. Mukherjee R, Locke KT, Miao B, Meyers D, Monshizadegan H, Zhang R, Search D, Grimm D, Flynn M, O'Malley KM et al. 2008 Novel peroxisome proliferator-activated receptor α agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. Journal of Pharmacology and Experimental Therapeutics 327 716-726.
73. Natsume H, Sasaki S, Kitagawa M, Kashiwabara Y, Matsushita A, Nakano K, Nishiyama K, Nagayama K, Misawa H, Masuda H et al. 2003 Beta-catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochemical and Biophysical Research Communications 309 408-413.
74. Nelson CC, Hendy SC & Romaniuk PJ 1995 Relationship between P-box amino acid sequence and DNA binding specificity of the thyroid hormone receptor. The effects of sequences flanking halfsites in thyroid hormone response elements. Journal of Biological Chemistry 270 16988-16994.
75. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK & Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395 137-143.
76. Ocasio CA & Scanlan TS 2006 Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist. ACS Chemical Biology 1 585-593.
77. OliverWR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH et al. 2001 A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. PNAS 98 5306-5311.
78. Plateroti M, Gauthier K, Domon-Dell C, Freund J-N, Samarut J & Chassande O 2001 Functional interference between thyroid hormone receptor α (TRα) and natural truncated TRΔα isoforms in the control of intestine development. Molecular and Cellular Biology 21 4761-4772.
79. Rastinejad F, Perlmann T, Evans RM & Sigler PB 1995 Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 375 203-211.
80. Redonnet A, Groubet R, Noel-Suberville C, Bonilla S, Martinez A & Higueret P 2001 Exposure to an obesity-inducing diet early affects the pattern of expression of peroxisome proliferator, retinoic acid, and triiodothyronine nuclear receptors in the rat. Metabolism 50 1161-1167.
81. Ricote M, Li AC, Willson TM, Kelly CJ & Glass CK 1998 The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 79-82.
82. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA & Evans RM 1998 Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Medicine 4 1058-1061.
83. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C et al. 1998 Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Medicine 4 1046-1052.
84. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM & Eng C 1999 Loss-of-function mutations in PPAR γ associated with human colon cancer. Molecular Cell 3 799-804.
85. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE & Freeman BA 2005 Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. PNAS 102 2340-2345.
86. Schrader M, Muller KM, Nayeri S, Kahlen JP & Carlberg C 1994 Vitamin D3-thyroid hormone receptor heterodimer polarity directs ligand sensitivity of transactivation. Nature 370 382-386.
87. Sedliarou I, Matsuse M, Saenko V, Rogounovitch T, Nakazawa Y, Mitsutake N, Namba H, Nagayama Y & Yamashita S 2007 Overexpression of wild-type THRbeta1 suppresses the growth and invasiveness of human papillary thyroid cancer cells. Anticancer Research 27 3999-4009.
88. Short J, Klein K, Kibert L & Ove P 1980 Involvement of the lodothyronines in liver and hepatoma cell proliferation in the rat. Cancer Research 40 2417-2422.
89. Shureiqi I, JiangW, Zuo X,Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM & Lippman SM 2003 The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPARdelta to induce apoptosis in colorectal cancer cells. PNAS 100 9968-9973.
90. Suzuki H, Willingham MC & Cheng SY 2002 Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12 963-969.
91. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A & Hosokawa M 2001 Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Research 61 2424-2428.
92. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL & Green S 1992 The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO Journal 11 433-439.
93. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD, Kratchmarova I, Berge RK, Iversen L, Bolund L et al. 2001 Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. Journal of Investigative Dermatology 116 702-712.
94. Williams GR 2000 Cloning and characterization of two novel thyroid hormone receptor beta isoforms. Molecular and Cellular Biology 20 8329-8342.
95. Willson TM, Brown PJ, Sternbach DD & Henke BR 2000 The PPARs: from orphan receptors to drug discovery. Journal of Medicinal Chemistry 43 527-550.
96. Wrutniak-Cabello C, Casas F & Cabello G 2001 Thyroid hormone action in mitochondria. Journal of Molecular Endocrinology 26 67-77.
97. Ying H, Suzuki H, Zhao L,Willingham MC, Meltzer P & Cheng SY 2003 Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor γ during thyroid carcinogenesis. Cancer Research 63 5274-5280.
98. Ying H, Araki O, Furuya F, Kato Y & Cheng SY 2007 Impaired adipogenesis caused by a mutated thyroid hormone alpha1 receptor. Molecular and Cellular Biology 27 2359-2371.
99. Zeng L, Geng Y, Tretiakova M, Yu X, Sicinski P & Kroll TG 2008 Peroxisome proliferator-activated receptor-delta induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors. Cancer Research 68 6578-6586.
100. Zhou-Li F, Albaladejo V, Joly-Pharaboz MO, Nicolas B & Andre J 1992 Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. Endocrinology 130 1145-1152.
101. Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM & Shureiqi I 2009 Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. Journal of the National Cancer Institute 101 762-767.